EXOZ logo

EXOZYMES INC

EXOZNASDAQ
πŸ† #4437 by market capEarnings Mar 29US Equity
$2.91β–Ό $0.47 (βˆ’14.05%)
Market closed Β· at close
πŸ””
Track EXOZ
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 14.1%
7dβ–Ό 29.7%
14dβ–Ό 29.7%
30dβ–Ό 24.6%
ytdβ–Ό 74.9%
1yβ–Ό 81.9%
🏦Market Cap
$27M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.84 – $3.31
52-Week Range
$2.81 – $16.48
Volume (shares)
10,823
Avg Volume (shares)
β€”
Shares Outstanding
9.4M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-2.5
P/S Ratio
0.0x
EPS (TTM)
$-1.09
Dividend Yield
0.00%
Dilution (1yr)
+3.1%
EXOZ logo

EXOZYMES INC

EXOZ
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$10Mβ–² +63.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$7Mβ–Ό βˆ’25.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.4Mβ–² +3.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mβ–Ό βˆ’$7M YoY
StockOtter Β· stockotter.space

About EXOZYMES INC

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

AccesswireΒ·Oct 21

eXoZymes CEO to Discuss Commercialization, Key Milestones, and Potential Catalysts in Fireside Chat with Water Tower Research

October 22 investor event will explore eXoZymes' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead. LOS ANGELES, CA / ACCESS Newswire / October 21, 2026 / Today, eXo

TheNewswireΒ·Oct 2

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"

October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, β€œConverting Cell-Free Science into a Scalabl

Defense WorldΒ·Sep 17

Head to Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) vs. eXoZymes (NASDAQ:EXOZ)

Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) and eXoZymes (NASDAQ: EXOZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength

AccesswireΒ·Sep 8

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027 LOS ANGELES, CA / ACCESS Newswire / September 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of A

Defense WorldΒ·Aug 22

eXoZymes Q2 Earnings Call Highlights

eXoZymes (NASDAQ: EXOZ) outlined progress toward commercializing its NCT program, including a reported tenfold increase in process productivity versus its March pilot campaign, while management said it expects to select